Tim Smith is an Assistant Editor at MJH Life Sciences. He focuses on themes related to medicine and healthcare, including dermatology, mental health care, immunology, and remote healthcare, blending his political science background with multimedia journalism. Tim's work has been featured in notable publications such as Commercial Observer, The Telegraph, and Fortune, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Tim Smith's articles predominantly focus on healthcare and pharmaceuticals, specifically dermatology, medical research, FDA approvals, skin conditions, and allergies. His content heavily relies on data citations for credibility.
If reaching out to Tim with a pitch or as a source, ensure that the information provided is backed by credible data and scientific evidence. Experts in dermatology, medical researchers specializing in skin conditions and allergies may find success in pitching insights related to new findings or treatment approaches supported by robust data.
Given the absence of geographic focus in Tim's coverage attributes makes it clear that he covers topics from a global perspective without specific regional constraints.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Catch up on dermatology news from January 2026, expert insights on dermatologic disease management, and more.
Investigators assessed the efficacy of switching to upadacitinib in those with atopic dermatitis who had an inadequate response to dupilumab.
This release by Apogee Therapeutics highlights findings from the phase 2 APEX trial on zumilokibart (APG777) in adults with moderate to severe atopic dermatitis.
By: Tim Smith
These data from REMIX-1 and 2 suggest remibrutinib, in those with chronic spontaneous urticaria (CSU), can lead to fast, early symptom control.
Discover why AR/VR is transforming experiential marketing and how immersive technology helps brands create engaging digital experiences with MovingStone Digital
By: Tim Smith
The durability of both skin clearance and itch reduction extended up to 4 years of lebrikizumab use in this assessment of adults and adolescents with atopic dermatitis.
This review of dermatology news from the first quarter of 2026 highlights key headlines, FDA news, and more.
By: Tim Smith
These new dermatology guidelines represent the first-ever atopic dermatitis-centered guidelines for pediatric patients issued by the AAD.
By: Tim Smith
Knowing what to spot, coaching people and managers to give mental health first aid and reviewing internal processes are among actions East Midlands Chamber recommends for firms in the region as Mental Health Awareness Week begins.
By: Tim Smith
Channel 5 News Chief Meteorologist Tim Smith traveled to Louisiana to see the work firsthand.
